PDL BioPharma (PDLI) has been under a strong bear grip, hence the stock is down -18.58% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 2.45% in the past 1 week. The stock has risen by 1.78% in the past week indicating that the buyers are active at lower levels, but the stock is down -18.75% in the past 4 weeks.
Company shares have received an average consensus rating of Hold for the current week The stock has recorded a twenty day Moving Average of 5.52% and the fifty day Moving Average is 9.65%. PDL BioPharma, Inc. has dropped 13.12% during the last three month period . Year-to-Date the stock performance stands at -16.7%.
PDL BioPharma (PDLI) has been rated by 2 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $4 and the lowest price target forecast is $4. The average forecast of all the analysts is $3.75 and the expected standard deviation is $0.35.
PDL BioPharma (NASDAQ:PDLI): stock turned positive on Friday. Though the stock opened at $2.73, the bulls momentum made the stock top out at $2.88 level for the day. The stock recorded a low of $2.71 and closed the trading day at $2.86, in the green by 4.38%. The total traded volume for the day was 1,692,730. The stock had closed at $2.74 in the previous days trading.
PDL BioPharma, Inc., manages a portfolio of patents and royalty assets, consisting of its Queen et al. patents, license agreements with various biotechnology and pharmaceutical companies, and royalty and other assets acquired. The Company provides non-dilutive growth capital and financing solutions to late-stage public and private healthcare companies and offers immediate financial monetization of royalty streams to companies, academic institutions, and inventors. It is focused on intellectual property asset management, acquiring new income generating assets and maximizing value for its stockholders. The Company receives royalties on a number of marketed products that use its technology and it has liscensed a number of humanized antibody products in late-stage clinical trials. As of December 31, 2014, the Company received royalties on sales of the ten humanized antibody products, which include Avastin, Herceptin, Xolair, Lucentis, Perjeta, Kadcyla, Tysabri, Actemra, Gazyva and Entyvio.